Aivo Biosciences, Inc.
Biotechnology company developing small-molecule CNS therapeutics focused on M1 muscarinic receptor agonism. The team emphasizes medicinal chemistry to generate brain-penetrant, highly potent and subtype-selective small molecules and is advancing a lead M1 agonist candidate through preclinical development toward IND-enabling studies and first-in-human evaluation. Leadership reports experience across preclinical and clinical development, manufacturing, business development and fundraising.
Industries
N/A
Nr. of Employees
small (1-50)
Aivo Biosciences, Inc.
Products
Lead M1 muscarinic receptor agonist candidate
A highly potent, subtype-selective, brain-penetrant small-molecule M1 receptor agonist candidate advanced through discovery and preclinical optimization toward IND-enabling studies.
Lead M1 muscarinic receptor agonist candidate
A highly potent, subtype-selective, brain-penetrant small-molecule M1 receptor agonist candidate advanced through discovery and preclinical optimization toward IND-enabling studies.
Services
End-to-end small-molecule drug discovery and preclinical development focused on CNS indications, with pathways toward IND-enabling studies and clinical proof-of-concept.
Engagement with prospective collaborators and investors through conferences, partnered meetings, and corporate presentations to support partnerships and commercialization.
End-to-end small-molecule drug discovery and preclinical development focused on CNS indications, with pathways toward IND-enabling studies and clinical proof-of-concept.
Engagement with prospective collaborators and investors through conferences, partnered meetings, and corporate presentations to support partnerships and commercialization.
Expertise Areas
- Small-molecule medicinal chemistry for CNS
- GPCR-targeted drug discovery (muscarinic M1)
- Preclinical and clinical development
- IND-enabling regulatory preparation
Key Technologies
- Small-molecule medicinal chemistry
- In silico modeling / computational chemistry
- Mass spectrometry
- In vitro pharmacology assays
News & Updates
Company leadership will meet prospective partners to explore collaboration opportunities focused on development and commercialization of the lead M1 agonist candidate; program advancing toward IND-enabling studies.
Company CEO presented a corporate overview and hosted one-on-one partnering meetings at ChinaBio 2025 in Shanghai.
Participation in industry showcase and partnering events to engage investors and potential collaborators regarding the lead M1 muscarinic receptor agonist candidate and clinical acceleration plans.
CEO participated as expert speaker on a panel about development challenges for muscarinic agonists including clinical learnings and subtype selectivity.
Company leadership will meet prospective partners to explore collaboration opportunities focused on development and commercialization of the lead M1 agonist candidate; program advancing toward IND-enabling studies.
Company CEO presented a corporate overview and hosted one-on-one partnering meetings at ChinaBio 2025 in Shanghai.
Participation in industry showcase and partnering events to engage investors and potential collaborators regarding the lead M1 muscarinic receptor agonist candidate and clinical acceleration plans.
CEO participated as expert speaker on a panel about development challenges for muscarinic agonists including clinical learnings and subtype selectivity.